Intranasal (IN) is a minimally invasive alternative route of administration. One reason it is a preferred method is because it precisely delivers the drugs from blood to brain, bypassing the blood brain barriers (BBB) and alleviating the hepatic first pass mechanism. Ascendia Pharmaceutical Solutions is experienced in developing effective nanoparticle-based formulations to overcome the challenges associated with intranasal delivery, making us your CDMO of choice for such projects.
In the review article entitled Intranasal delivery of nano-formulation: A potential way of treatment for neurological disorders (Molecules, 2020, 25, 1929), Islam et al. describe the innovative ways to overcome BBB barriers for efficient delivery. It states that there are multiple routes to transport the small or large molecules through BBB, including paracellular of water soluble through diffusion or transcellular through tight junction if they are insoluble/lipophilic or lipid soluble. Carrier transport proteins and receptor mediated mechanisms also play important roles in transporting these molecules across the BBB..jpg?width=400&height=356&name=noise%20brain%20delivery%20(002).jpg)
Nanoparticles for CNS Disorder Treatment
All these mechanisms play crucial roles for targeting and treating a range of central nervous system (CNS) disorders, such as Alzheimer’s disease, Parkinson’s disease, epilepsy, multiple sclerosis, glioblastoma, and meningitis. Nanoparticles comprised of a different class of lipids and/or polymers with smaller particles and larger surface areas and having the abilities to penetrate deeper, can improve through absorption in the nasal cavity to the brain.
The Islam et al. (2020) article also sheds light on the impact of nanoparticle size in the delivery of drugs from the blood to the brain. Engineered particles 100 nm in size can penetrate the olfactory bulb and deliver to the brain. Particles that are 900 nm are unable to penetrate the brain, states the article.
PLGA - Poly(lactic-co-glycolic acid) - is a highly versatile and biocompatible copolymer with large surface area and surface modification with targeting ligands. Alghareeb et al. (2024), in a recent article entitled PLGA nanoparticles for nasal delivery (J. Drug Delivery Tech., 2024, 95, 105564), demonstrates that PLGA can enhance drug delivery, cellular uptake, and bioavailability at target sites. Table 2 in the article lists a number of studies on PLGA nanoparticles used in nasal delivery of small and large molecules. This study coupled with other cited studies, demonstrate the utilities of PLGA in delivery of drugs via intranasal route of administration.
Experts in Nanoparticles
Ascendia Pharmaceutical Solution’s team is expert in nanoparticles (polymers and lipids). We also have cGMP manufacturing capabilities in our recently expanded U.S.-based facility in the New Jersey Bioscience Center that encompass an array of technical and manufacturing services. Our four S1 clean rooms have 100/10,000 classification and output capabilities of up to 30,000 units per batch to support a variety of sterile projects.
Our manufacturing facility meets the needs of clients interested in producing the clinical trial material (CTM) to commence Phase 1 and Phase 2 studies. Our state-of-the-art sterile manufacturing facilities coupled with lyophilization capabilities can help expedite the development from small R&D batches to scale up batches to save pharmaceutical and biopharma companies time and money.
You can learn more about our capabilities by reading two recent articles – PLGA – A versatile copolymer for design and development of nanoparticles for drug delivery, (J. Anal. Pharm. Res., 2023, 12, 72-78), which cites a number of drugs approved across all modalities, and Drug Development & Delivery, 2024, November/December.
Ascendia Pharmaceutical Solutions also invites you to explore our expertise and capabilities for manufacturing the nanoparticles of small and large molecules delivered via intranasal route of administration to target the brain.
Contact us today to discuss your project.